Navigation Links
Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
Date:6/16/2008

Cato Research Signed as Strategic Partner for the Phase 3 Program

LA JOLLA, Calif., June 16 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company developing non-invasive, topically administered medications, today announced the initiation of its Phase 3 clinical program for Ketotransdel(TM), its novel topical cream based non-steroidal anti-inflammatory drug ("NSAID") for pain. The Company has engaged Cato Research Ltd., a global contract research organization ("CRO"), as a strategic partner and as the CRO to conduct the Phase 3 clinical program.

The Company's randomized, double-blind, placebo controlled Phase 3 trial will evaluate the efficacy and safety of Ketotransdel(TM) for the topical treatment of acute pain from soft tissue injuries. Clinical sites are planned throughout the United States and potentially other regions, including Canada. The Company expects that Ketotransdel(TM), if approved by the U.S. Food and Drug Administration, could become the first topical NSAID cream product in the United States for acute pain management. The drug could address what the Company believes is a significant unmet medical need for patients and physicians seeking a potentially safer alternative to existing pain management approaches, such as oral NSAIDs.

"Advancing Ketotransdel(TM) into Phase 3 clinical studies is a significant milestone for our Company. Our top priority is to execute our clinical program as planned," said Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals. "For the conduct of the clinical trial we carefully evaluated only select top level CROs with extensive experience in the relevant pain area. We selected Cato Research not only due to their relationship as a strategic partner with us, but because of their cost efficient approach to the clinical program, expertise in the pain space and our direct access to their senior executive man
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
5. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
6. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
7. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
10. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
11. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... LOS ANGELES , May 24, 2013  An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...
(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer").  On 20 May 2013, ...
(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... 16, 2011 Cancer patients in China ... the announcement that a leading cancer center is acquiring ... VAR). This device is the first high dose rate ... leader in radiotherapy systems. Jilin University ...
... 16, 2011 U L ... announced today that it has filed an abbreviated 510(k) application ... label claim to include the management and mitigation of pain. ... a randomized clinical study comparing Altrazeal® to Acquacel® Ag in ...
Cached Medicine Technology:First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4
(Date:5/24/2013)... NY (PRWEB) May 24, 2013 ... (AICASA) has signed an articulation agreement with ... students to study abroad in Antigua. , ... college credits after participating in a cell biology course, ... articulation agreement with American University of Antigua (AUA) ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 The ... of products used outside the central laboratory, by ... a healthcare practitioner or by consumers. This includes ... fertility and pregnancy, infectious and cardiovascular disease and ... such as critical care, surgical and emergency departments. ...
(Date:5/24/2013)... than half of recommended well-child visits had up to ... attended most of their visits, according to a study ... Care . The study included more than 20,000 children ... chronic conditions like asthma and heart disease were even ... according to the study. In fact, children with ...
(Date:5/24/2013)... is available in German . ... "alpha-synuclein" aggregates and accumulates within neurons. Specific areas of ... and advances. The mechanism underlying this pathological progression is ... protein (or abnormal forms of it) along nerve projections ... the German Center for Neurodegenerative Diseases (DZNE) in Bonn ...
(Date:5/24/2013)... presented today shows that formation of new neurons in ... importance in learning and remembering - could cause forgetting ... brain circuits. Drs. Paul Frankland and Sheena Josselyn, ... argue this reorganization could have the positive effect of ... for new learning. These results were presented at ...
Breaking Medicine News(10 mins):Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:Young children who miss well-child visits are more likely to be hospitalized 2Health News:Young children who miss well-child visits are more likely to be hospitalized 3Health News:Proteins in migration 2Health News:Proteins in migration 3Health News:Proteins in migration 4Health News:New neuron formation could increase capacity for new learning, at the expense of old memories 2
... woman who dines with a man, chances are you choose food ... is one of the findings in a study conducted by researchers ... of the international journal Appetite . Meredith Young, PhD ... what a person chooses to eat at lunch or dinner is ...
... N.J., Aug. 5 Most people over the age of 40 ... on nearby objects. Although this age related phenomena is usually assisted ... in Tokyo, Japan and published in March, 2009 has shown significant ... subjects (mean age of 53.9 +/- 5.1 years) with supplementation of ...
... , FORT LAUDERDALE, Fla., Aug. 5 In ... Boston and Miami, discussions are now focusing on how massive recoveries ... health reform initiatives. This latest sweep was the third in two ... has recovered more than $370 million. , , ...
... WASHINGTON, Aug. 5 The National Council on Disability (NCD) ... people with disabilities at 9:45 a.m. on August 12 at ... Conference on Community Preparedness -- The Power ... Hotel, 2799 Jefferson Davis Highway, Arlington, VA. NCD Vice Chairperson ...
... ... combine industry-leading RFID software, services with industry-first RFID laser printing capabilities to create ... ... 5, 2009 -- Today, FileTrail Inc, the leading provider of browser-based records management software ...
... , , Goal to ... Agencies Should Empanel Scientific Advisory Committees Solely of Members ... , WASHINGTON, Aug. 5 A bipartisan panel ... on the White House and federal agencies to make specific ...
Cached Medicine News:Health News:What you eat depends on with whom you eat 2Health News:The Reduction of Eye Fatigue Improves Vision in Older Subjects 2Health News:Multi-state Medicare Fraud Crackdown Focuses Attention on Recovery Payoffs to Defray Health Reform Costs 2Health News:FileTrail Joins With Lexmark To Offer End-to-End RFID-Enabled Item Management, Tracking, and Printing Solutions 2Health News:FileTrail Joins With Lexmark To Offer End-to-End RFID-Enabled Item Management, Tracking, and Printing Solutions 3Health News:FileTrail Joins With Lexmark To Offer End-to-End RFID-Enabled Item Management, Tracking, and Printing Solutions 4Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 2Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 3Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 4Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 5Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 6
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: